###### Strengths and limitations of this study

-   This is the first review to map interventions trialled for individuals with Machado-Joseph disease (MJD) to enhance walking and moving around and to align findings with the 'Staying Strong' Framework.

-   Studies typically focussed on interventions that promote 'staying strong on the outside' (physically), with few targetting 'staying strong on the inside' (emotionally, mentally and spiritually).

-   This study is limited by a shortage of high-quality research that includes individuals specifically with MJD.

-   This review highlights opportunities for investigating the benefit of lifestyle activity programmes that address both physical and psychosocial well-being for families with MJD.

Introduction {#s1}
============

Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3, is an autosomal-dominant neurodegenerative disease. Individuals with MJD experience progressive cerebellar ataxia and decline in mobility caused by premature cell death in the cerebellum and brainstem.[@R1] Average life expectancy is 20 years from onset of symptoms, with most individuals wheelchair users within 10 years of symptoms emerging.[@R2] MJD is the most common spinocerebellar ataxia (SCA) worldwide[@R3] and is most prevalent in remote Aboriginal communities in the Top End of Australia. For example, prevalenace estimates for the Groote Eylandt Archipelago in Australia are \~743/100 000, compared with \~39/100 000 for the Azores Archipelago in Portugal, where MJD is also common.[@R4]

Many trials are underway to find a cure for a range of SCAs.[@R8] Other research efforts have focused on physiotherapeutic interventions to address impairments and activity limitations resulting from a range of hereditary ataxias (HAs).[@R10] These interventions have been shown to enhance mobility and potentially delay symptom progression.[@R14] For people with MJD, current recommended physiotherapeutic interventions are based on findings from studies on other SCAs.[@R13] A focus on MJD is required, given the differences in pathophysiology and neurochemistry between SCA types,[@R9] and to understand what interventions have been previously explored and where gaps lie. This information will provide future direction for targeted interventions for people with MJD to maximise their functional mobility.

Interventions designed to promote mobility for Aboriginal families with MJD from the Top End of Australia, whose culture and lifestyle are uniquely different to those with MJD in other parts of the world, have not been investigated.[@R18] Importantly, these interventions are unlikely to be effective if they do not incorporate Indigenous views and concepts of physical activity and lifestyle in line with cultural and traditional practices.[@R18]

Aboriginal families with MJD from the Groote Eylandt Archipelago have experienced the impact of MJD on their families for generations.[@R18] In a recent study,[@R21] these families shared their perspectives on what is important and what works best to keep walking and moving around.[@R18] Participants emphasised the importance of 'staying strong on the inside and outside' (physically, mentally, emotionally and spiritually) through 'exercising your body', 'keeping yourself happy', 'going country', 'searching for good medicine', 'families helping each other' and having 'something important to do'.[@R18] These domains formed the 'Staying Strong' Framework to keep walking and moving around; a framework driven by community and culturally founded needs ([table 1](#T1){ref-type="table"}).[@R18] This review set out to explore: (1) What interventions/strategies have been explored to promote walking and moving around for people with MJD (2); How the findings of these explorations align with the perspectives of families with MJD from Groote Eylandt, according to the domains of the 'Staying Strong' Framework.[@R18]

###### 

'Staying Strong' Framework

  Domains                       Definition
  ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Exercising your body          Having an active lifestyle and keeping your body moving every day keeps you physically strong (ie, going country, walking, hunting, fishing swimming, dancing, doing housework and yard work, riding a bike, walking on a treadmill).Exercising your body helps you cope with the worries and sadness that come with MJD.
  Something important to do     Finding something meaningful to do pushes you to keep your body moving and keep physically strong.Having something important to do helps you feel you are contributing to your family and community, sets an example for others and builds self-esteem and happiness.
  Keeping yourself happy        Finding ways to stay happy and positive, and drawing on family and support services when required, helps you keep persevering in life despite having MJD.It helps you to keep doing the things you need to do to stay physically strong.Feeling low and unhappy can make you feel physically weak.
  Searching for good medicine   Searching for good medicine or food from the natural environment, or useful clinical medicines, is important for staying physically and emotionally strong.It is important to find good medicines that help you to manage other illnesses that negatively impact living with MJD (colds, flus, infections and pain).For Aboriginal people of Groote Eylandt, finding traditional medicines in the bush or beach is important for staying active and keeping physically and emotionally strong.
  Going country                 Going country means getting out and about, to places meaningful to the individual, to do things that matter, with people that matter, to keep yourself both physically and emotionally strong.For Aboriginal families of Groote Eylandt, going country involves getting out of the home, visiting their lands, at the bush or beach, often to go hunting or fishing with family.
  Families helping each other   Family support is important for having opportunities to keep physically strong and for physical assistance as the disease progresses.Support from families offers important emotional support, keeping you strong inside.Family extends to local and trusted service providers.

MJD, Machado-Joseph disease.

Methods and analysis {#s2}
====================

A scoping review was conducted following the five-step approach recommended by Arksey and O'Malley and further developed by Levac *et al*.[@R22] A scoping review was chosen to allow a broad range of topics across a range of study types and designs to be explored, to identify the nature and extent of research evidence available.[@R24] The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) extension for Scoping Reviews Checklist was followed.[@R25] This review was not registered with PROSPERO as scoping reviews are not currently accepted.

Relevant studies {#s2-1}
----------------

A comprehensive search of peer-reviewed published literature was conducted for studies published from 1990 when genetic confirmation of MJD became possible,[@R26] until August 2018. The search was repeated prior to publication to identify studies published up to July 2019. Using MEDLINE, EMBASE, CINAHL, PsychINFO and Cochrane Databases, a combination of medical subject headings terms and keywords with truncations were used ([table 2](#T2){ref-type="table"}). The search was initially broad to include all HAs, to ensure inclusion of studies with participants with multiple aetiologies including MJD would be identified. Studies were chosen if they (1) included human participants with genetically confirmed MJD either exclusively or within the study sample, (2) included adolescents and/or adults, (3) included at least one measure of mobility, function or ataxia and (4) explored the influence of any intervention/strategy on mobility and/or function using objective measures or from the perspective of the participant. In studies that did not disclose the types of SCA of included participants, authors were contacted to confirm inclusion or exclusion on this basis.

###### 

Search terms (MEDLINE)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Concept                                                                                                                      Search terms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Limits
  ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------
  What\                                                                                                                        program\* or promot\* or interven\* or strateg\* or approach\* or train\* or rehab\* or princip\* or therap\* or support\* or motivat\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Nil
  (*interventions*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Works best\                                                                                                                  benefi\* or improv\* or positiv\* or significan\* or maint\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Nil
  (*promote, enhance*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  People with MJD\                                                                                                             cerebellar ataxia/ or exp spinocerebellar ataxias/ or spinocerebellar degenerations/ or friedreich ataxia/ or olivopontocerebellar atrophies/ or 'spinocerebellar ataxia\*' or 'machado joseph disease' or 'friedreich's ataxia' or 'inherited olivopontocerebellar atrophy' or 'cerebello-olivary atrophy' or 'spinocerebellar degeneration' or 'genetic degenerative ataxia' or 'cerebellar ataxia' or 'hereditary ataxia' or 'genetic ataxia' or 'inherited ataxia' or 'dentatorubral pallidoluysian atrophy' or 'trinucleotide repeat dis\*' or 'inherited neurodegenerative dis\*' or 'degenerative ataxia' or 'hereditary neurodegenerative ataxia\*' or 'autosomal dominant hereditary ataxia\*' or 'autosomal recessive hereditary ataxia\*'   Nil
  (*initially broadened search to HAs to ensure all studies that may have included participants with MJD could be screened*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Walking and moving around\                                                                                                   exp Movement/ or exp Human Activities/ or exp Locomotion/ or Physical Mobility/ or Motor Activity/ or Stair Climbing/ or walk\* or mobil\* or function\* or move\* or moving or activit\* or step\* or stand\* or transfer\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Nil
  (*functional mobility*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HAs, hereditary ataxias; MJD, Machado-Joseph disease.

Study selection and quality assessement {#s2-2}
---------------------------------------

Database searches were conducted by one reviewer (JJC) and verified by a second reviewer (JQ). Both reviewers (JJC and JQ) independently screened titles and abstracts and reviewed full-text articles. Additional studies screened for inclusion were identified by handsearching reference lists of included studies, literature reviews that met the eligibility criteria and through citations tracked using Google Scholar.[@R1] The PRISMA flow diagram outlines the results of the search ([figure 1](#F1){ref-type="fig"}).[@R32] The second search found no new studies that met the inclusion criteria.

![Flow diagram of study selection.](bmjopen-2019-032092f01){#F1}

Methodological quality assessment of included studies, not typically required of scoping reviews, was employed to identify gaps in the literature and quality of the studies available.[@R33] Two reviewers (JJC and MS) assessed methodological quality of included studies using the Mixed Method Appraisal Tool (MMAT)[@R34] and classified them according to the National Health and Medical Research Council (NHMRC) evidence hierarchy.[@R35] The MMAT was selected as this single tool allowed quality appraisal of the range of study designs relevant to this review (qualitative, randomised controlled (RCTs), non-RCTs and quantitative descriptive studies). Joanna Briggs Institute (JBI) Levels of Evidence for Meaningfulness[@R36] was used to grade level of evidence for the qualitative study[@R37] and the expert opinion excerpt.[@R1] Disagreements were resolved by consensus or referred to a third reviewer (RNB).

Data extraction, collation and analysis {#s2-3}
---------------------------------------

To facilitate analysis and reporting, data were extracted using NVivo V.12[@R38] following a data extraction guide. Data extracted included study characteristics, participant characteristics, intervention characteristics, outcome measures and study outcomes. Data gathered were charted into tables.[@R22] Measures of blood chemistry, neuroimaging or measures of upper limb function were not extracted unless included in composite or functional outcome measures, such as the Spinocerebellar Ataxia Functional Index (SCAFI).

All studies found were collated and then mapped according to the domains they aligned to in the 'Staying Strong' Framework (JJC). Studies that aligned to more than one domain were mapped under the domain to which they most strongly aligned ([table 3](#T3){ref-type="table"}). A descriptive approach was used to analyse the data collected.[@R39] To provide an overview, key points that highlight each study's alignment with the different domains were compiled in a separate table ([online supplementary table 1](#SP1){ref-type="supplementary-material"}). Meta-analysis was not possible due to heterogeneity of outcome measures and interventions in the included studies.
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###### 

Summary of studies exploring interventions to promote walking and moving around for people with MJD

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Staying strong domain: exercising your body                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  --------------------------------------------- --------------------------------------------- --------- ---------- ---------------- ---------------------- ---------- ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------- -------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Wang *et al* 2018\                            RCT                                           II        \*\*\*\*   n=9;\            Exp:\                  Ambulant   Exergames training vs conventional balance +coordination training                                      4                                                              3                                      40 min                                              SARA (I)Limit of stability test (A)Spatiotemporal gait parameters (A)                                                                                                                                                                                                                                                                                                                                                        Pre and post                                                                                                         Between groups: not significant\
  China                                                                                                            MJD              54 (51--60)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Within group (exp group):Improved SARA gait-posture (p=0.038)\*, SARA total (p=0.042)\*
                                                                                                                                    Control: 57 (44--61)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Kaut *et al*\                                 Pseudo RCT                                    III-1     \*\*\*\*   n=31;\           Exp:\                  Ambulant   Stochastic vibration therapy vs sham                                                                   8 days                                                         4 sessions total                       5×60 s on/60 s off                                  SARA (I)SCAFI (A)INAS (I)                                                                                                                                                                                                                                                                                                                                                                                                    Pre and post                                                                                                         Between groups: not significant\
  2014\                                                                                                            MJD (n=2)\       61.2 (12.3)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Within group (exp group):Improved SARA gait and posture (p\<0.01)\*, 8MWT (p=0.02)\*
  Germany                                                                                                          SCA1\            Control:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                   SCA2\            57.3 (12.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                   SCA6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Conte *et al*\                                Non-randomised experimental trial             III-2     \*\*\*\*   n=13;\           50.2 (9.5)             Ambulant   Wide BOS walking vs walking between two white lines (width determined by healthy controls)             6×10 m walking trials per session, 1 min rest between trials   2 walking sessions on\                 Gait speed matched to healthy controls              Spatiotemporal gait parameters (A)Upper body and lower body kinematics (A)Muscle coactivation (A)Energy recovery and expenditure (I)                                                                                                                                                                                                                                                                                         Each session recorded                                                                                                Between groups: not significant\
  2017\                                                                                                            MJD (\#)\                                                                                                                                                                                                                2 separate days\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Within group:Narrow BOS walking: reduced speed\*, step length\*, hip and knee ROM\*, energy recovery\*; increased double support,\* gait variability,\* trunk oscillation,\* ankle joint muscle coactivation\*Widened BOS walking---increased dynamic stability\*; reduced compensatory mechanisms\*, mechanical energy\*
  Italy                                                                                                            SCA1\                                                                                                                                                                                                                    1 week interval between days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   SCA2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   SAOA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Tabbassum *et al* 2013\                       Non-randomised experimental trial             III-2     \*         n=20;\           Not reported           Ambulant   Core stability training+balance training vs balance training+relaxation                                4                                                              3                                      1 hour/day                                          BESTest (A)MFES (Falls) (A)                                                                                                                                                                                                                                                                                                                                                                                                  Pre and post4 weeks post                                                                                             Between groups (exp group):BEStest each assessment\*Not significant: MFES
  India                                                                                                            MJD (\#)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                   SCA1\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   SCA2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   SCA3\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   OPCA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Fonteyn *et al*\                              Case series with pretest/post-test outcomes   IV        \*\*\*\*   n=10;\           61.4 (5.7)             Ambulant   Gait adaptability training on treadmill with visual cues on treadmill                                  5                                                              2                                      6 gait adaptability exercises for 60 min\           Obstacle avoidance task success rate (A)SARA (I)10MWT (A)TUG (A)BBS (A)EFAP (A)ABC (A)No of falls (A)Experience of training questionnaire (Q)                                                                                                                                                                                                                                                                                1-week pre1-week post                                                                                                Between groups: NA\
  2014\                                                                                                            MJD (n=1)\                                                                                                                                                                                                                                                      No handrail used. Difficulty gradually progressed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Within group:Improved SARA and EFAP obstacle subtask\*, increased short-step strategy preference (p=0.003)\*, success rates increased (78.5%--94.8%)\*Not significant: BBS, TUG, 10MWT, Obstacle Avoidance Task
  The Netherlands                                                                                                  SCA6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   SAOA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Im *et al*\                                   Case series with pretest/post-test outcomes   IV        \*\*\*\*   n=19;\           53.2 (13.8)            Ambulant   Task specific walking training: part practice (weight shifting, stepping)+whole practice of walking\   12                                                             2                                      1.5 hours each session                              ICARS (I)Spatiotemporal gait parameters (A)                                                                                                                                                                                                                                                                                                                                                                                  Pre and post3 months post                                                                                            Between groups: NA\
  2017\                                                                                                            MJD (n=3)\                                         Manual support provided and weaned as required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Within group:Improved ICARS each assessment\*; reduced spatiotemporal gait parameter variability\*
  Korea                                                                                                            SCA2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   SCA6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   Idiopathic\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                   MSA-C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Leonardi *et al* 2017\                        Case series with pretest/post-test outcomes   IV        \*\*\*\*   n=9;\            35.3 (16.3)            Ambulant   Wearable proprioceptive stabiliser+conventional balance training\                                      Device wear: 3\                                                Device wear: 5\                        Device wear:\                                       SARA (I)6MWT (A)Spatiotemporal gait parameters (A)                                                                                                                                                                                                                                                                                                                                                                           Pre and post 3 weeks of device wear (T1)+usual training3 weeks postdevice discontinuation+usual training only (T2)   Between groups: NA\
  Italy                                                                                                            MJD (n=2)\                                         (limit of stability training+external perturbations practice in protected conditions)                  Usual balance training:\                                       Usual balance training: 5              3 (hour)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Within group:Improved SARA\*, 9HPT-dominant hand\*, PATA\*, 6MWT\*, spatiotemporal gait parameters (T1)\*, length of gait cycle (T2)\*
                                                                                                                   SCA1\                                                                                                                                                     6                                                                                                     Usual balance training: 40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                   SCA2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   FA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  de Oliveira *et al* 2018\                     Case series with pretest/post-test outcomes   IV        \*\*       Stage 1: n=9\    43 (11)                Ambulant   PBWS treadmill training:\                                                                              Stage 1:8\                                                     2 (days)                               50 min                                              CPET (A)BORG (A)BBS (A)DGI (A)SARA (I)BARS (I)Katz ADL (Q)Treadmill inclination (A)                                                                                                                                                                                                                                                                                                                                          Prestage 1 (S0)Prestage 2 (S1)Poststage 2 (S2)                                                                       Between groups: NA\
  Brazil                                                                                                           Stage 2: n=5\                                      Stage 1: CV training\                                                                                  Stage 2:10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Within group:S1: Improved DGI (p=0.03)\*, CPET duration (p\<0.01)\*, treadmill inclination (p\<0.01)\*S2: Improved BBS compared with S1 (p=0.04)\*Not significant: SARA, Katz ADL, BARS, VE peak/VO2 max
                                                                                                                   MJD (n=6)\                                         Stage 2: dynamic balance training                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                   SCA1\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   SCA7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  de Oliveira *et al* 2015\                     Case series with pretest/post-test outcomes   IV        \*\*\*\*   n=11;\           46.1 (range 28--59)\   Ambulant   Balance training                                                                                       4                                                              2--3                                   1 (hour)                                            BBS (A)                                                                                                                                                                                                                                                                                                                                                                                                                      Pre and post                                                                                                         Between groups: NA\
  Brazil                                                                                                           MJD (n=8)\       SD not reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Within group:Improved BBS (p=0.0034)\*
                                                                                                                   SCA2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   SCA7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Sawant and Gokhale\                           Case series with pretest/post-test outcomes   IV        \*\*\*     n=3;\            24.6 (3.4)             Ambulant   Occupational therapy+intensive functional physical training\                                           12                                                             5\                                     45 min--1 hour                                      BBS (A)FIM+FAM (A)                                                                                                                                                                                                                                                                                                                                                                                                           Pre and post                                                                                                         Between groups: NA\
  2015\                                                                                                            MJD (n=1)\                                         (tailored programme meaningful to participant)                                                                                                                        (supervised=3; home/ unsupervised=2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Within group:Improved BBS (p=0.05)\*, FIM+FAM (p=0.01)\*
  India                                                                                                            Hereditary SCA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Silva *et al*\                                Case series with pretest/post-test outcomes   IV        \*\*\*\*   n=23;\           42.4 (10)              Ambulant   Occupational therapy: training priorities on functional limitations                                    6 months                                                       Once/week:\                            40 min                                              FIM (A)Barthel Index (A)Hamilton rating scale (Q)WHOQOL-BREF (Q)NESSCA (I)SARA (I)                                                                                                                                                                                                                                                                                                                                           Pre and postMid intervention                                                                                         Between groups: NA\
  2010\                                                                                                            MJD                                                                                                                                                                                                                      0--3 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Within group:Improved Hamilton depression score at 6 months (p\<0.0001)\*Not significant: FIM, Barthel Index, WHOQOL-BREF
  Brazil                                                                                                                                                                                                                                                                                                                                    Once/month:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                            3--6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  D'Abreu *et al*\                              Review (expert opinion section)               V (JBI)   NA         n=23;\           NA                     NA         NA                                                                                                     NA                                                             NA                                     NA                                                  Recommendations:Physical therapy assessment +exercise programme.Falls assessment and assistive device prescriptionTrial levodopa for those with dystonia affecting mobilityExercise improves ability to cope, increases self-esteem, boosts patients' mood and sense of control over their disease.Source of pain should be identified and managed appropriately (musculoskeletal/neuropathic/secondary to dystonia/mixed)                                                                                                                        
  2010\                                                                                                            MJD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Brazil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Staying strong domain: searching for good medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ---------------------------------------------------- ---------------------------------------------------- ----------- ---------- ---------------- ----------------------- --------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Assadi *et al*\                                      RCT                                                  II          \*\*\*     n=19\            40.5 (17.3)             Not stated                  Buspirone HCl\                                                                                            Each treatment arm: 12\                              Twice daily                                                      NA                                                                            ICARS (I)                                                                                                                                                                                                                                                                     Pre and post each treatment phase                                                             Between groups: not significant
  2007\                                                                                                                            MJD (n=2)\                                                           30 mg twice daily vs placebo\                                                                             2 weeks of each arm consisted of titration period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  USA                                                                                                                              SCA1\                                                                Crossover after\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   SCA2\                                                                4 week washout                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                   SCA17\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                   FA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                   Idiopathic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Lei *et al*\                                         RCT                                                  II          \*\*       n=34\            Multidose exp:\         Ambulant                    Valproic acid\                                                                                            12                                                   Twice daily                                                      NA                                                                            SARA (I)                                                                                                                                                                                                                                                                      PredoseWeek 4Week 8Week 12                                                                    Between groups:Improved SARA in 1200 mg/day group (−2.05) compared with 800 mg/day (−1.58) and placebo (−0.75) (p=0.021)\*Improved SARA subscores in placebo and VPA groups (800 mg/day and 1200 mg/day) (p\<0:05)\*
  2016\                                                                                                                            MJD              800 mg: 36.5 (5.4)\                                 low-dose VPA (800 mg/day), high-dose VPA (1200 mg/day) vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  China                                                                                                                                             1200 mg: 33.9 (7.1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                    sham:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                    33.9 (4.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Saute *et a* *l*ˆˆ\                                  RCT                                                  II          \*\*\*\*   n=60\            Exp:\                   Ambulant                    Lithium carbonate vs placebo                                                                               48                                                  300 mg once/day; increased to twice daily until 0.5--0.8 mEQ/L   NA                                                                            NESSCA (I)SARA (I)8MWT (A)SCAFI (A)CCFS (A)Barthel Index (A)WHOQOL-BREF (Q)BDI (Q)PGI (Q)                                                                                                                                                                                     Pre dose24 weeks48 weeks                                                                      Between groups (exp group):Improved SCAFI (24, 48 week)\*; CCFS (48 week)\*Not significant ---NESSCA, SARA, 8MWT, 9HPT, BDI, Barthel Index, WHOQOL-BREF, PGI
  2014\                                                                                                                            MJD              40.5 (9.6);\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Brazil                                                                                                                                            sham:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                    40.4 (9.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Schulte *et al*\                                     RCT                                                  II          \*\*       n=20\            44.7 (11)               Standing (minimum)          Trimethoprim-sulfamethoxazole\                                                                            Phase 1:\                                            Twice daily                                                      NA                                                                            Posturography (A)ACRS (I)SF36 (Q)                                                                                                                                                                                                                                             PrePost 2/52Post each 6 months treatment phase                                                Between groups: not significant
  2001\                                                                                                                            MJD                                                                  trimethoprim (160 mg)+sulfamethoxazole (800 mg) 2/52; trimethoprim\                                       6 months exp or placebo\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Germany                                                                                                                                                                                               (80 mg)+sulfamethoxazole (400 mg) remainder of 6 months                                                   Washout: 4\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                  Phase 2:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                  crossover to alternate preparation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Wessel *et al*\                                      RCT                                                  II          \*\*\*     n=18\            46.8\                   Not stated                  Physostigmine (30 mg) patch vs sham patch                                                                 Each treatment arm: 4\                               Patch worn continuously                                          24 hour/day                                                                   ACRS (I)Posturography (A)                                                                                                                                                                                                                                                     Pre and post each treatment phase                                                             Between groups: not significant
  1997\                                                                                                                            MJD (n=2)\       SD not reported                                                                                                                                               Washout: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Germany                                                                                                                          SCA1\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   idiopathic CA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Zesiewicz *et al*\                                   RCT                                                  II          \*\*\*     n=13\            Exp\                    Not stated                  Varenicline\                                                                                              8                                                    Max dose, twice daily                                            NA                                                                            SARA (I)T25FWT (A)BDI (Q)BAI (Q)CGI (I)PGI (Q)SF36 (Q)                                                                                                                                                                                                                        Pre and post                                                                                  Between groups (exp group)Improved SARA subs scores (gait, stance, rapid alternating movements)\*, T25FWT\*, BDI (p\<0.05)\*Not significant: CGI, PGI, BAI, SF36
  2012\                                                                                                                            MJD              47.44 (10.83); Sham:\                               4 weeks for titration and 4 weeks at 1 mg twice daily                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  USA                                                                                                                                               53.78 (11.18)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Shiga *et al*\                                       Non-randomised experimental trial                    III-2       \*\*\*     n=74\            Exp:\                   Ambulant                    TMS over cerebellum vs sham                                                                               21 days                                              Once daily                                                        10 pulses Pulse duration: 0.1 ms Output adjusted to 100% of maximum output   10MWT (A)Walking capacity (A)Standing capacity (A)Tandem steps (A)                                                                                                                                                                                                            Pre and post                                                                                  Between groups (exp group):Improved 10MWT time (p\<0.05)\*, 10 m steps (p\<0.05)\*, tandem steps (p\<0.005)\*, standing capacities (p\<0.05)\*\
  2002\                                                                                                                            MJD (\#)\        58.83 (1.47)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Within group (sham group):Improved 10 m time (p\<0.05)\*, 10 m steps (p\<0.05)\*, standing capacities (p\<0.05)
  Japan                                                                                                                            sporadic OPCA\   Sham:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                   SCA1\            56.31 (1.96)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                   SCA6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Liu *et al*\                                         Interrupted time series without a parallel control   III-3       \*\*\*     n=6\             27\                     Ambulant                    Lamotrigine                                                                                               Week 0--1:\                                          25 mg daily                                                      NA                                                                            TGI (A)OLS (A)                                                                                                                                                                                                                                                                Weekly(0--9 week)                                                                             Between groups: NA\
  2005\                                                                                                                            MJD              SD not reported                                                                                                                                               No meds\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Within groups:Improved TGI with LTG (p\<0.05; week 4, 5, 6, 7)\*, OLS scores (p\<0.05; week 7)\* but not during withdrawal
  Taiwan                                                                                                                                                                                                                                                                                                          Week 2--7:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                  LTG (6 weeks)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                  Week 8--9: Withdrawal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Arpa *et a* *l*\                                     Case series with pretest/post-test outcomes          IV          \*\*\*\*   n=12\            51 (13)                 Not stated                  Human IGF-1 (subcutaneous administration)                                                                 2 years                                              Twice daily                                                      0.05 mg/kg                                                                    SARA (I)                                                                                                                                                                                                                                                                      Pre4 months8 months12 months16 months20 months24 months                                       Between groups: NA\
  2015\                                                                                                                            MJD (7)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Within group:Improved SARA for SCA3 after IGF-1 treatment at 8 months (p=0.0061)\*
  Spain                                                                                                                            SCA7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Giordano *et al*\                                    Case series with pretest/post-test outcomes          IV          \*\*       n=14\            60 (11.3)               Ambulant                    Slow release 4-Aminopyridine                                                                              14 days                                              Once daily                                                       2×10 mg                                                                       SARA (I)EQ-5D (Q)8MWT (A)SCAFI (A)                                                                                                                                                                                                                                            Pre4 hour post 4-AP14 days post 4-AP                                                          Between groups: NA\
  2013\                                                                                                                            MJD (2)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Within group:Improved SCAFI after 4 hours and after 14 days (p=0.01)\*, 8MWT after 14 days\*, but not after 4 hours (p\<0.01)\*Not significant: SARA, 9HPT, EQ-5D
  Germany                                                                                                                          SCA1\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   SCA6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   ADCA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   POLG\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   SAOA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Monte *et al*\                                       Case series with pretest/post-test outcomes          IV          \*\*       n=13\            41 (13)                 Ambulant                    Fluoxetine                                                                                                6                                                    Once daily                                                       20 mg                                                                         EDSS (A)UPDRS (A)                                                                                                                                                                                                                                                             Pre and post                                                                                  Between groups: NA\
  2003\                                                                                                                            MJD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Within group: not significant
  Brazil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Sanz-Gallego *et al* 2014\                           Case series with pre/post-test outcomes              IV          \*\*\*     n=26\            SCA3: 50.3 (13)\        Ambulant                    IGF-1 therapy                                                                                             12 months                                            Twice daily                                                      NA                                                                            SARA (I)SF36 (Q)                                                                                                                                                                                                                                                              Pre4 months8 months12 months                                                                  Between groups: NA\
  Spain                                                                                                                            MJD (n=19)\      Total: 49.3 (14.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Within group:Improved SARA (p=0.013), 8 and 12 months) in SCA3\* and SCA7 subgroups after 12 months (p values not provided)\*SF36: 18.5% were dissatisfied, 14.8% had poor satisfaction, 37% had fair satisfaction, and 29.6% showed high satisfaction over study durations
                                                                                                                                   SCA6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   SCA7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Takei *et al*\                                       Case series with pretest/post-test outcomes          IV          \*\*\*     n=10\            41.9 (2.4)              Ambulant and non-ambulant   Tandospirone\                                                                                             7\                                                   Once daily                                                       NA                                                                            ARS (I)TLT (A)SDS (Q)Leg pain questionnaire (I)                                                                                                                                                                                                                               ARS:Week 0, 4, 5, 7SDS:Week 0, 4, 5, 6Leg pain questionnaire: Week 0, 4, 5, 6TLT:Week 0-- 7   Between groups: NA\
  2004\                                                                                                                            MJD                                                                  15 mg/day, increased to 30 mg/day after 1 week                                                            Week 0--1:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Within group:Improved ARS (from week 3) and SDS (from week 2) (p\<0.05)\*; Increased ICARS in withdrawal but decreased significantly to lower than pre-therapy level after restart (p\<0.05)\*TLT reduced in 5/7 patients more than 10%Leg pain alleviated in 5/7 patients (significance level not provided)Not significant: SDS
  Japan                                                                                                                                                                                                                                                                                                           Nil therapy\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                  Week 1--4: Tandospirone\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                  Week 5: Withdrawal\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                  Week 6--7:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                  Follow-up with Tandospirone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Takei *et al*\                                       Case series with pre-test/post-test outcomes         IV          \*\*       n=39\            52.4 (14.5)             Ambulant                    Tandospirone\                                                                                             4                                                    Once daily                                                       NA                                                                            ICARS (I)TLT (A)SDS (Q)                                                                                                                                                                                                                                                       Pre and post                                                                                  Between groups: NA\
  2010\                                                                                                                            MJD (n=14)\                                                          15 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Within group:Improved ICARS (p=0.005) (MJD)\*, TLT (p=0.002) (MJD)\*SDS (significance not reported): 5/14 MJD scored\>50 indicating depression; 3/5 improved to\<50 after therapy
  Japan                                                                                                                            SCA1\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   SCA2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   SCA6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   MSA-C\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                   MSA-P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Tsai *et al*\                                        Case series with pretest/post-test outcomes          IV          \*\*\*\*   n=7\             41.57\                  Not stated                  Adipose mesenchymal stem cells                                                                            Once                                                 Once                                                             NA                                                                            SOT---posturography (A)SARA (I)                                                                                                                                                                                                                                               1 month before baseline0.5, 1, 3, 6, 9 and 12 months after AD-MSC                             Between Groups: NA\
  2017\                                                                                                                            MJD (n=6)\       (range 21--66)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Within group:Improved SOT (p\<0.05 at 3 and 6 months) (MJD)\*Not significant: SARA
  Taiwan                                                                                                                           MSA-C            SD not reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Yang *et al*\                                        Case series with pretest/post-test outcomes          IV          \*\*\*     n=30\            43.14 (12.77)           Not stated                  Stem cell treatment+balance training                                                                      4--6 weeks                                           Stem cells:\                                                     Stem cells;\                                                                  BBS (A)                                                                                                                                                                                                                                                                       Pre and post                                                                                  Between groups -- NA\
  2011\                                                                                                                            MJD (n=5)\                                                                                                                                                                                                                          4-- 6 times\                                                     15--30 min\                                                                                                                                                                                                                                                                                                                                                                                                                                               Within group:Improved BBS (p=0.0001)\*
  China                                                                                                                            SCA1\                                                                                                                                                                                                                               (5--7 day interval)\                                             Balance training: 30 min/session                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                   SCA2\                                                                                                                                                                                                                               Balance training:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                   SCA6\                                                                                                                                                                                                                               Twice daily                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                   Unknown\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                   FA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Berntsson *et al*\                                   Qualitative                                          III (JBI)   \*\*\*     n=4\             56.7\                   Not stated                  NA---qualitative investigation on patients' experiences with cerebellar ataxia and intrathecal baclofen   NA                                                   NA                                                               NA                                                                            Overall theme: Living in the present/taking 1 day at a time.\                                                                                                                                                                                                                                                                                                               
  2017\                                                                                                                            MJD (n=1)\       (range 51--72)\                                                                                                                                                                                                                                                                                                                                                   Main categories:Uncertainty about the futureImpact on life as a wholeFeeling forced to terminate employmentLimiting daily activities: helped manage cramps =+ve impact on mobilityIntrathecal baclofen therapy: 3/4 recommended baclofen. Other participant not discussed.\                                                                                                 
  Scandinavia                                                                                                                      SCA4\            SD not reported                                                                                                                                                                                                                                                                                                                                                   +ves: improved control of body, improved sleep quality\                                                                                                                                                                                                                                                                                                                     
                                                                                                                                   SCA\                                                                                                                                                                                                                                                                                                                                                                               -ves: Increased body weight                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                   FA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Staying strong domain: keeping yourself happy                                                                                                                                                                                                                                                                                                                                                    
  ----------------------------------------------- --------------------------------------------- ---- ---------- ---------------- ------------------- ------------ --------------------------------------------------------------------------------- ---- ---------------------------------------- --------- ---------------------------------------- --------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lo *et al*\                                     Case series with pretest/post-test outcomes   IV   \*\*\*\*   n=295\           SCA3: 51.1 (12.4)   Not stated   No intervention.\                                                                 NA   NA                                       NA        SARA 9I)UHDRS-IV (A)PHQ-9 (Q)EQ-5D (Q)   Baseline6 months12 months18 months24 months   Depression common in SCAs (26%); signiﬁcantly higher in SCA3Depression associated with SARA but did not signiﬁcantly progress over time or deteriorate with increased CAG repeatsDepression signiﬁcantly impacted negatively on functional status and QOL in all SCAs, independent of ataxia progression
  2016\                                                                                                         MJD (n=123)\                                      Evaluated the prevalence and inﬂuence of depressive symptoms on people with SCA                                                                                                                                                  
  Taiwan/USA                                                                                                    SCA1\                                                                                                                                                                                                                                                                              
                                                                                                                SCA2\                                                                                                                                                                                                                                                                              
                                                                                                                SCA6                                                                                                                                                                                                                                                                               

  Sawant and Gokhale\                             Case series with pretest/post-test outcomes   IV   \*\*\*     n=3\             24.6 (3.4)          Ambulant     Occupational therapy+intensive functional physical training\                      12   5\                                       0.45--1   BBS (A)FIM+FAM (A)                       Prior to interventionPost intervention        Between groups: NA\
  2015\                                                                                                         MJD (n=1)\                                        (tailored programme meaningful to participant)                                         (supervised=3; home or unsupervised=2)                                                                                                    Within group:Improved BBS (p=0.05)\*, FIM+FAM (p=0.01)\*
  India\                                                                                                        Hereditary SCA                                                                                                                                                                                                                                                                     
  (also reported in 'exercising your body')                                                                                                                                                                                                                                                                                                                                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Symbols: (?), Participant numbers per condition not provided; ˆˆ, randomised, double-blind, placebo-controlled---dose-controlled study phase analysed only; +, combined with; \*, significance change \<0.005.

ABC, Short version of Activities-specific Balance Scale; ACRS, Ataxia clinical rating scale; 4-AP, 4-Aminopyridine; BAI, Beck Anxiety Inventory; BARS, Brief Ataxia Rating Scale; BBS, Berg Balance Scale; BDI, Beck Depression Inventory; BESTest, Balance Evaluation System Test; BORG, Borg rating of perceived exertion scale; BOS, base of support; CCFS, Composite Cerebellar Functional Score; CGI, Clinical Global Impression; COM, Centre of MASS; CPET, Cardiopulmonary Exercise Test; CV, cardiovascular; DGI, Dynamic gait index; EDSS, Extended Disability Status Scale of Kurtzke; EFAP, Emory Functional Ambulation Scale: Obstacle subtask; EQ-5D, EuroQol health related quality of life measure; Exp, experimental group; FA, Friedreich's ataxia; FIM, Functional Independence Measure; FIM+FAM, Functional Independence Measure + Functional Assessment Measure; 25FWT, Timed 25-foot walk test; 9HPT, 9-hole peg test; 9HPT, 9-hole peg test; ICARS, International Cooperative Ataxia Rating Scale; IGF-1, Insulin-like growth factor; INAS, Inventory of Non-Ataxia Symptoms; JBI, Joanna Briggs Institute Levels of Evidence for Meaningfulness; Katz ADL, Katz index of independence in activities of daily living; LTG, Lamotrigine; mEQ/L, milliequivalents per litre; MFES, Modified Falls Efficacy Scale; mg, milligrams; MJD, Machado-Joseph disease; MMAT, Mixed Methods Appraisal Tool; MSA-C, multisystems atrophy-cerebellar ataxia predominates; MSA-P, multisystems atrophy-Parkinson's type; 6MWT, 6-minute walk test; 8MWT, 8-minute walk test; 10MWT, Timed 10m walk test; NESSCA, Neurological Examination Score for SCA; NHMRC, National Health and Medical Research Council; OLS, one leg standing; OPCA, olivopontocerebellar atrophy; PBWS, partial body weight support; PGI, Patient Global Impression; PHQ-9, Patient health questionnaire; QOL, quality of life; RCT, randomised controlled trials; ROM, Range of movement; S, Significant difference within groups; SAOA, sporadic adult-onset ataxia of unknown origin; SARA, Scale for Assessment and Rating of Ataxia; SCA, spinocerebellar ataxia; SCAFI, SCA Functional Index: Incudes 9HPT, 8MWT, PATA syllables within 10 sec test (PATA); SDS, Self-rating depression scale; SF36, short form 36 health survey; SOT, sensory organisation test; TGI, Tandem Gait Index; TLT, total length travelled; TMS, Transcutaneous Magnetic Stimulation; TUG, Timed Up and Go Test; UHDRS-IV, Unified Huntington's Disease Rating Scale; UPDRS, Unified Parkinson's Disease Rating Scale; WHOQOL-BREF, World Health Organisation Quality of Life Questionnaire.

Patient and pubic involvement {#s2-4}
-----------------------------

There was no patient or public involvement in this study.

Results {#s3}
=======

A total of 30 studies met the eligibility criteria and included quantitative (experimental (n=27); observational (n=1)) and qualitative (n=1) designs. One expert opinion excerpt (n=1) that was eligible and included was extracted from a literature review that otherwise did not meet the eligibility criteria. Twelve different countries were represented (Brazil (n=6), Germany (n=4), China (n=3), Japan (n=3), Taiwan (n=3), USA (n=3), India (n=2), Italy (n=2), Spain (n=2), Korea, the Netherlands and Scandinavia. Characteristics of the included studies are outlined in [table 3](#T3){ref-type="table"}.

Study population {#s3-1}
----------------

Of the 30 studies, 12 studies included MJD participants exclusively. The remaining 18 included participants with both MJD and other HAs. Mobility status was reported as ambulant in 21 studies, able to stand at a minimum in one study, while eight studies did not report mobility status. Study sample sizes ranged from eight to 295 participants, with a total of 850 participants, 429 with MJD (50.5%). Age ranged from 15 to 76 (average across all studies=46.7 years).

Methodological quality {#s3-2}
----------------------

Seven quantitative studies were graded level II (RCTs) according to NHMRC levels of evidence.[@R30] The remaining studies were graded III-1 (one study),[@R46] III-2 (three studies),[@R47] III-3 (one study)[@R50] and IV (16 studies).[@R51] The qualitative study was graded level 3[@R37] and the expert opinion excerpt was graded level 5[@R1] in accordance with the JBI Levels of Evidence for Meaningfulness.[@R36] MMAT scores for methodological quality are provided in [table 4](#T4){ref-type="table"}. Quality scores ranged as follows \*(n=1),[@R48] \*\*(n=6),[@R41] \*\*\*(n=10)[@R30] and \*\*\*\*(n=12).[@R40] The expert opinion excerpt was not scored.[@R1]

###### 

Quality assessment of included studies using the Mixed Methods Appraisal Tool (MMAT)\*

  Author(s)†                  Qualitative   Quantitative RCT   Quantitative non-random   Quantitative descriptive   Total   Score                                                 
  --------------------------- ------------- ------------------ ------------------------- -------------------------- ------- ------- --- --- --- --- --- --- --- --- --- --- ----- -----
  Arpa *et al* 2015                                                                                                                         1   1   1   1                   4/4   100
  Assadi *et al* 2007                                                                                               0       1       1   1                                   3/4   75
  Berntsson *et al* 2017      0             1                  1                         1                                                                                  3/4   75
  Conte *et al* 2017                                                                                                                        1   1   1   1                   4/4   100
  de Oliveira *et al* 2015                                                                                                                  1   1   1   1                   4/4   100
  de Oliveira *et al* 2018                                                                                                                  1   0   1   0                   2/4   50
  Fonteyn *et al* 2014                                                                                                                      1   1   1   1                   4/4   100
  Giordano *et al* 2013                                                                                                                     0   1   0   1                   2/4   50
  Im *et al* 2017                                                                                                                           1   1   1   1                   4/4   100
  Kaut *et al* 2014                                                                                                 1       1       1   1                                   4/4   100
  Lei *et al* 2016                                                                                                  0       0       1   1                                   2/4   50
  Leonardi *et al* 2017                                                                                                                     1   1   1   1                   4/4   100
  Liu *et al* 2005                                                                                                                          0   1   1   1                   3/4   75
  Lo *et al* 2016                                                                                                                                           1   1   1   1   4/4   100
  Monte *et al* 2003                                                                                                                        0   1   0   1                   2/4   50
  Sanz-Gallego *et al* 2014                                                                                                                 1   1   1   0                   3/4   75
  Saute *et al* 2014                                                                                                1       1       1   1                                   4/4   100
  Sawant and Gokhale 2015                                                                                                                   0   1   1   1                   3/4   75
  Schulte *et al* 2001                                                                                              0       0       1   1                                   2/4   50
  Shiga *et al* 2002                                                                                                                        0   1   1   1                   3/4   75
  Silva *et al* 2010                                                                                                                        1   1   1   1                   4/4   100
  Tabbassum *et al* 2013                                                                                                                    0   1   0   0                   1/4   25
  Takei *et al* 2004                                                                                                                        0   1   1   1                   3/4   75
  Takei *et al* 2010                                                                                                                        0   1   1   0                   2/4   50
  Tsai *et al* 2017                                                                                                                         1   1   1   1                   4/4   100
  Wang *et al* 2018                                                                                                 1       1       1   1                                   4/4   100
  Wessel *et al* 1997                                                                                               0       1       1   1                                   3/4   75
  Yang *et al* 2011                                                                                                                         1   0   1   1                   3/4   75
  Zesiewicz *et al* 2012                                                                                            1       1       1   0                                   3/4   75

\*A mixed-methods studies column was not included as no mixed-method studies were reviewed.

†D'Abreu *et al* 2010 was not scored (expert opinion excerpt).

1, criterion met; 0, criteria not met or unable to determine; RCT, randomised controlled trials.

Outcome measures {#s3-3}
----------------

Fifty-three different outcome measures were used to investigate interventions in this review. The SARA scale (14/30 studies) was the measure most commonly used. Outcome measures included measures at the impairment level (ataxia, disease severity and depression), measures at the activity level (function, mobility and balance) and measures of quality of life (QOL). No studies included measures at the participation level. [Table 5](#T5){ref-type="table"} presents measures used, as well as outcomes that reached statistical significance.

###### 

Summary of outcome measures and results+

                                   Wang *et al*                Kaut *et al*   Conte *et al*   Tabbassum *et al*   Fonteyn *et al*   Im *et al*   Leonardi *et al*   de Oliveira *et al* 2018   de Oliveira *et al* 2015   Sawant and Gokhale 2015   Silva *et al*   D'Abreu *et al*   Assadi *et al*   Lei *et al*   Saute *et al*ˆˆ   Schulte *et al*   Wessel *et al*   Zesiewicz *et al*   Shiga *et al*   Liu *et al*   Arpa *et al*   Giordano *et al*   Monte *et al*   Sanz-Gallego *et al*   Takei *et al*   Takei *et al*   Tsai *et al*   Yang *et al*   Berntsson *et al*   Lo *et al*   
  -------------------------------- --------------------------- -------------- --------------- ------------------- ----------------- ------------ ------------------ -------------------------- -------------------------- ------------------------- --------------- ----------------- ---------------- ------------- ----------------- ----------------- ---------------- ------------------- --------------- ------------- -------------- ------------------ --------------- ---------------------- --------------- --------------- -------------- -------------- ------------------- ------------ --
  Impairment                       ACRS                                                                                                                                                                                                                                                                                                                  NS               NS                                                                                                                                                                                                                        
  BARS                                                                                                                                                              NR                                                                                                                                                                                                                                                                                                                                                                                                                              
  ICARS                                                                                                                             **\***                                                                                                                                            NS                                                                                                                                                                                                             **\***          **\***                                                                         
  INAS                                                         NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Leg pain questionnaire                                                                                                                                                                                                                                                                                                                                                                                                                                                                             NR                                                                                             
  NESSCA                                                                                                                                                                                                                                            NS                                                               NS                                                                                                                                                                                                                                                                             
  SARA                             **\***                      **\***                                             **\***                         **\***             NS                                                                              NS                                                 **\***        NS                                                   \*BG                                              **\***         NS                                 **\***                                                 NS                                                X            
   Activity                        6MWT                                                                                                                             **\***                                                                                                                                                                                                                                                                                                                                                                                                                          
  8MWT                                                                                                                                                                                                                                                                                                               NS                                                                                                                    **\***                                                                                                                                                   
  ABC                                                                                                             NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Barthel Index                                                                                                                                                                                                                                     NS                                                               NS                                                                                                                                                                                                                                                                             
  BBS                                                                                                             NS                                                **\***                     **\***                     **\***                                                                                                                                                                                                                                                                                                                    **\***                                          
  BEStest                                                                                     \*BG                NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  BORG                                                                                                                                                              NS                                                                                                                                                                                                                                                                                                                                                                                                                              
  CCFS                                                                                                                                                                                                                                                                                                               \*BG                                                                                                                                                                                                                                                                           
  CGI\*                                                                                                                                                                                                                                                                                                                                                                   NS                                                                                                                                                                                                                        
  CPET                                                                                                                                                              **\*ˆ**                                                                                                                                                                                                                                                                                                                                                                                                                         
  DGI                                                                                                                                                               **\***                                                                                                                                                                                                                                                                                                                                                                                                                          
  EDSS                                                                                                                                                                                                                                                                                                                                                                                                                                                        NS                                                                                                                                    
  EFAP                                                                                                            **\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Energy recovery/expenditure                                                 **\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  FIM/FIM-AM                                                                                                                                                                                                              \*                        NS                                                                                                                                                                                                                                                                                                                                              
  Kinematic recordings                                                        **\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ˆLimit of stability test         NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  MFES (Falls)                     NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                   Muscle coactivation (EMG)                                  **\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Obstacle avoidance success                                                                                      **\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  OLS                                                                                                                                                                                                                                                                                                                                                                                                         **\***                                                                                                                                                                                
  No of falls                                                                                                     NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Posturography                                                                                                                                                                                                                                                                                                      NS                                                                                                                                                                                              **\***                                                                         
  SCAFI                            **\***                                                                                                                                                                                                                                                              \*BG                                                                                                   **\***                                                                                                                                                                                
  Spatiotemporal gait parameters   NR                                         **\***                                                **\***       **\***                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Standing capacity                                                                                                                                                                                                                                                                                                                                                       \*BG                                                                                                                                                                                                                      
  25FWT                                                                                                                                                                                                                                                                                                                                                                   \*BG                                                                                                                                                                                                                      
  10MWT                                                                                                           NS                                                                                                                                                                                                                                                      \*BG                                                                                                                                                                                                                      
  TGI/tandem steps                                                                                                                                                                                                                                                                                                                                                        \*BG                SS                                                                                                                                                                                                    
  Total length travelled                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **\***          **\***                                                                         
  Treadmill inclination (%)                                                                                                                                         **\***                                                                                                                                                                                                                                                                                                                                                                                                                          
  TUG                                                                                                             NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  UHDRS-IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             X            
  UPDRS                                                                                                                                                                                                                                                                                                                                                                                                                                                       NS                                                                                                                                    
  Walking capacity                                                                                                                                                                                                                                                                                                                                                                            NS                                                                                                                                                                                                    
   QOL\#                           BAI                                                                                                                                                                                                                                                                                                                                                        NS                                                                                                                                                                                                    
  BDI                                                                                                                                                                                                                                                                                                                NS                                                   \*BG                                                                                                                                                                                                                      
  EQ-5D                                                                                                                                                                                                                                                                                                                                                                                                                                    NS                                                                                                                                          X            
  Experience of training Q                                                                                        NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Hamilton rating scale                                                                                                                                                                                                                             \*                                                                                                                                                                                                                                                                                                                                              
  KATZ ADL                                                                                                                                                          NS                                                                                                                                                                                                                                                                                                                                                                                                                              
  PGI global impression                                                                                                                                                                                                                                                                                              NS                                                   NS                                                                                                                                                                                                                        
  PHQ-9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                X            
  SDS                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NR                     NR                                                                                             
  SF36                                                                                                                                                                                                                    NS                        NS                                                                                                   NR                                                                                                                                                                                                                                         
  WHOQOL-Bref                                                                                                                                                                                                             X                         NS                                                                                                                                                                                                                                                                                                                                              

Symbols: \*, significant difference within groups or significant difference presingle and postsingle group; \*BG, significant difference between groups; \*ˆ, significant difference in CEPT duration. No significant change in VE peak or VO2 max; ˆ, activity and impairment measure; \#, includes measures for depression, well-being and overall health; +, Note: only outcome measures clinically relevant to function and mobility shown (ie imaging results for brain glucose metabolism and brain metabolite ratios have been excluded); X, relationship between variables assessed only. Nil intervention. See [table 3](#T3){ref-type="table"} for findings.

ABC, Short version of Activities-specific Balance Scale; ACRS, Ataxia Clinical Rating Scale; BAI, Beck Anxiety Inventory; BARS, Brief Ataxia Rating Scale; BBS, Berg Balance Scale; BDI, Beck Depression Inventory; BES test, Balance Evaluation System Test; BORG, Borg Rating of Perceived Exertion Scale; CCFS, Composite Cerebellar Functional Score; CGI, Clinical Global Impression; CPET, Cardiopulmonary Exercise Test; DGI, Dynamic Gait Index; EDSS, Extended Disability Status Scale of Kurtzke; EFAP, Emory Functional Ambulation Scale: Obstacle subtask; EQ-5D, EuroQol health related quality of life measure; FIM/FIM-AM, Functional Independence Measure + Functional Assessment Measure; 25FWT, 25-foot walk test; ICARS, International Cooperative Ataxia Rating Scale; INAS, Inventory of Non-Ataxia Symptoms; KATZ ADL, Katz index of independence in activities of daily living; MFES (Falls), Modified Falls Efficacy Scale; 6MWT, 6-min walk test; 8MWT, 8 metre walk test; 10MWT, Timed 10 min walk test; NESSCA, Neurological Examination Score for SCA; OLS, one leg standing; PGI, Patient Global Impression; PHQ-9, Patient health questionnaire; Q, questionnaire; QOL, quality of life; SARA, Scale for Assessment and Rating of Ataxia; SCAFI, SCA Functional Index: Incudes 9HPT, 8MWT, PATA syllables within 10s test (PATA); SDS, Self-rating Depression Scale; SF-36, Short form 36 health survey; TUG, Timed Up and Go Test; UHDRS-IV, Unified Huntington's Disease Rating Scale; UPDRS, Unified Parkinson's Disease Rating Scale; WHOQOL-BREF, World Health Organisation Quality of Life Questionnaire.

Adverse events {#s3-4}
--------------

Nine studies reported adverse events, all within pharmacological studies. None were considered serious or life threatening.[@R30] One study reported two-drop outs due to side effects, but details of the effects were not specified.[@R64]

Study setting {#s3-5}
-------------

Of the 27 experimental studies, 12 were conducted under supervision of a health professional in the outpatient setting,[@R40] two of which included an additional unsupervised home programme.[@R52] In the remaining 15 studies, participants self-administered medications in their homes.[@R30] The qualitative[@R37] and longitudinal observational studies[@R61] were conducted face to face in an outpatient Neurology clinic. Study setting was not relevant to the expert opinion excerpt.[@R1] Assessments were carried out in the inpatient setting in three studies,[@R41] outpatient setting for 12 studies,[@R30] both in two studies,[@R41] while all follow-up took place in the outpatient setting.

Interventions {#s3-6}
-------------

A range of interventions have been explored, both pharmacological and non-pharmacological. Overall, no pharmacological interventions are currently recommended for use by indivudals with MJD. Non-pharmacological, exercise-based interventions, have had a positive impact on walking and moving around. Intervention types have been described under each of their corresponding domains in the 'Staying Strong' Framework (see [table 3](#T3){ref-type="table"} and [online supplementary table 1](#SP1){ref-type="supplementary-material"}). In relation to the International Classification of Functioning, Disability and Health framework,[@R67] no interventions in this review targeted the participation level, but focussed predominantly on the body functions and structures level and activity level.

Exercising your body {#s3-7}
--------------------

Thirteen studies discussed interventions which aligned with 'exercising your body'.[@R1] Exercise in general was reported to be beneficial in one study.[@R1] Specific interventions could be separated into three types of training: (1) walking training, (2) task specific training and (3) balance training. All studies related to 'exercising your body' reported significant findings, although only three of the 13 studies had a control group. Interventions varied in type, duration and frequency. Intervention sessions occurred on average for 51 min duration, 2.7 times a week for 8 weeks. Dosages such as repetitions completed per session or intensity, in terms of effort per session, were not reported. Rest periods were reported in one study.[@R47]

### Walking practice {#s3-7-1}

Four studies investigated interventions that aligned to walking practice[@R47] including training on a treadmill,[@R56] over ground walking[@R59] and walking with a wide base of support.[@R47] All significantly improved either balance,[@R47] ataxia[@R56] and/or walking ability.[@R47]

### Task-specific training {#s3-7-2}

Two studies investigated task-specific training through ADL training alone[@R52] or in combination with strength, balance, coordination, walking and cycling training.[@R63] ADL training alone significantly improved depression scores,[@R52] but when combined with other task-specific training, balance and function also improved significantly after 12 weeks.[@R63]

### Balance practice {#s3-7-3}

Six studies explored interventions to challenge balance: balance training alone[@R62] or in conjunction with 'exergames'[@R40]; a wearable proprioceptive stabiliser[@R60]; core stability training[@R48]; stochastic vibration therapy[@R46] and task-specific training.[@R63] Significant improvements (both between and within groups) in balance,[@R48] ataxia severity[@R40] and walking[@R46] were found. One study combined stem cell therapy with balance training (see below in 'searching for good medicine').[@R57]

Searching for good medicine {#s3-8}
---------------------------

Seventeen studies evaluated interventions that aligned with 'searching for good medicine'. Fourteen different pharmacological interventions were explored, one in combination with balance training,[@R57] as well as one non-pharmacological intervention (transcutaneous magnetic stimulation (TMS)). No studies evaluated traditional medicine or complementary medicine use.[@R68] One study (expert opinion) recommended medications to minimise the sequalae of impairments as a result of MJD (ie, levodopa for dystonia, pain relief for pain).[@R1] While some therapies demonstrated potential to reduce ataxia (valproic acid,[@R41] lithium carbonate,[@R42] varenicline)[@R45] and improve function (lithium carbonate,[@R42] TMS),[@R49] efficacy had not been demonstrated. None of the interventions were recommended for use by individuals with MJD[@R9] ([table 3](#T3){ref-type="table"}).

Keeping yourself happy {#s3-9}
----------------------

Two studies aligned with 'keeping yourself happy'.[@R37] Depression was found to have a significant negative impact on functional status and QOL, independent of ataxia, with suicidal ideation more common in MJD than in SCA1, SCA2 or SCA6.[@R61] Participants living with ataxia shared the devastating impact of the disease on their social life, mood, parental roles, ADLs and employment, but recommended living in the present and taking 1 day at a time.[@R37] Exercise was reported to help individuals with MJD cope and gain a sense of control over their disease.[@R1] However, only one study explored individualised interventions designed to promote both physical and psychosocial well-being.[@R52] Nine studies included measures of QOL or depression to evaluate their intervention[@R42] but only two studies[@R53] demonstrated significant improvements in those measures ([table 5](#T5){ref-type="table"}).[@R53] The remainder reported either non-significant findings or did not report significance levels.

Something important to do {#s3-10}
-------------------------

Two studies aligned with having 'something important to do'. Support from employers was important to maintain work roles.[@R37] Loss of meaningful employment, lack of support from employers or changes to roles as a parent or provider had a negative impact on mood and identity.[@R37] Only one study evaluated an intervention tailored to the goals/needs of the participant.[@R52] Depression scores improved, but measures of function and QOL failed to reach significance.[@R52] No other included studies explored goal orientated or task-specific training or training based on individual goals/priorities/interests.

Going country {#s3-11}
-------------

No studies aligned with 'going country'. All studies were conducted either in a hospital or research facility with the exception of two studies that included an unsupervised home programme.[@R52] No studies were found that explored 'going country', community participation, community engagement, vocational rehabilitation, outdoor mobility, sport and/or recreation in relation to mobility for individuals with MJD.

Families helping each other {#s3-12}
---------------------------

No studies aligned with 'families helping each other'. No studies considered the influence of family support, interventions or rehabilitation with family, or the role of families in supporting mobility and function for individuals with MJD.

Discussion {#s4}
==========

The purpose of this review was to map the range of interventions/strategies trialled for people with MJD to enhance walking and moving around and to align those interventions with the 'Staying Strong' Framework developed by individuals and families with MJD from the Groote Eylandt Archipeligo. Studies were typically of low quality and focused on what is largely staying strong on the outside: 'exercising your body' (walking training, balance training or task-specific training) and 'searching for good medicine' (various oral medicines, injectable medicines and non-pharmacological medicines). Few studies explored the impact on mobility of having 'something important to do' (ie, goal orientated, or task specific training based on individual goals/priorities/interests) or strategies for 'keeping yourself happy'. No studies in this review considered the impact on mobility of 'going country' (community participation, outdoor mobility, sport/recreation) or 'families helping each other' (the impact or relationship of family support on functional mobility). This review thereby highlights an opportunity for meaningful, individualised, person-centred interventions to promote physical and psychosocial function, consistent with the views of families with MJD in Australia,[@R18] and those living with ataxia in other parts of the world.[@R69]

Exercising your body {#s4-1}
--------------------

Overall, exercise or physical activity interventions were found to have positive effects on mobility for individuals with MJD and to be generally safe, inexpensive and in current use. The most effective interventions and the optimal dosage could not be determined, due to heterogeneity of outcome measures and study designs. However, studies that engaged participants in at least 50 min training, at least 2--3 times each week, for approximately 4 weeks, demonstrated improvement. This finding is consistent with ataxia research more broadly, that has shown higher intensity rehabilitation to be more effective (60 min, 2 days per week) than less intensive training.[@R11] Interestingly, no studies evaluated incidental physical activity or participants' level of activity outside of the intervention, unlike studies in other progressive conditions including Huntington's disease (HD), multiple sclerosis and Parkinson's disease (PD) literature.[@R71] Programmes and interventions that promote participation and an active lifestyle have well known benefits on mobility and well-being for individuals living with neurological disorders.[@R73] Yet the amount of exercise suggested to bring benefit for people with MJD and other ataxias[@R11] suggests that lifestyle-orientated programmes that extend well beyond a 4-week intervention are required.[@R74]

Searching for good medicine {#s4-2}
---------------------------

Consistent with perspectives of families with MJD from the Groote Eylandt Archipelago,[@R18] this review highlights the continued search for good medicine for individuals with MJD. The impact of traditional medicines or nutritional supplements on functional mobility for those with MJD has not been studied as it has in HD and PD.[@R75] Furthermore, none of the many medications that were evaluated are currently indicated for MJD with most studies assessing drug safety with small samples. Notwithstanding, in this review, individuals with MJD were better represented in pharmacological studies than in studies on physiotherapeutic interventions. While large sample size recruitment is an inevitable challenge in rare disease research,[@R16] sample homogeneity within studies will be important moving forward to generate strong clinical recommendations for those with MJD.[@R9] Consistent with other ataxias, current recommendations for pharmacological management for those with MJD relate largely to managing the sequalae of disease, such as spasticity, sleeping difficulties and incontinence.[@R1]

Going country {#s4-3}
-------------

In this study and across all SCAs, research to explore community-based interventions in the context of an individual's environment or lifestyle is lacking, despite known benefits of engagement in sport, recreation and leisure activities for those with disabilities.[@R77] Dance and participation in sport are some activities that have been evaluated for those with other neurodegenerative conditions.[@R78] While *going country* may be culturally and contextually specific to Aboriginal families with MJD in the Top End of Australia, individuals with ataxia in other parts of the world share similar views, relevant to their own context.[@R80] Participation in outdoor sports, self-developed exercises, team sports or community-based exercise classes, while beneficial physically, have also been found to promote self-esteem and well-being.[@R70] Outdoor activities have helped individuals with ataxia manage depression and focus on living life to the fullest.[@R70] Individuals with MJD generally remain ambulant up to 10 years following onset of symptoms,[@R4] leaving opportunities for engagement in sport and recreational activities outside of a facility and in the community. Impairment focused intervention programmes restricted to indoor clinical facilities may overlook functional benefits that could be gained through participation in interventions that are fun, enjoyable and meaningful to the person.[@R70] Research to evaluate the benefits of such interventions on mobility is warranted, for those with MJD and HAs more broadly.

Something important to do and keeping yourself happy {#s4-4}
----------------------------------------------------

Disappointingly, having 'something important to do' and 'keeping yourself happy' were discussed minimally in the literature. The impact of depression on QOL for people with SCAs is alarming, particularly the significantly higher rates of suicidal ideation for those with MJD.[@R61] While a number of studies in this review included measures of depression and QOL,[@R42] interventions tested appeared to have little impact on either. The sensitivity of the measures used over the generally short intervention period should be taken into consideration.[@R82] On the other hand, this may highlight a need for more individualised interventions that target both physical and psychosocial well-being more effectively. The importance of self-selected meaningful exercise has been echoed by individuals with other degenerative ataxias, finding self-chosen activities that offer physical challenge and personally meaningful rewards, provide a sense of achievement, satisfaction and motivation to carry on.[@R70] While evaluation of the efficacy of individualised interventions does present challenges,[@R83] programmes such as ParkFIT for PD in the Netherlands[@R84] and Engage-HD for people with HD in the UK[@R71] have provided examples on how these challenges can be overcome.[@R73]

Families helping each other {#s4-5}
---------------------------

It is perhaps surprising, considering MJD is an autosomal-dominant disease, that no studies discussed the inclusion of family members as study participants. The devastating impact families face with autosomal-dominant neurodegenerative diseases is well known.[@R86] While family support, peer socialisation and support through physical activity is a facilitator for engagement in physical activity for people with neurodegenerative diseases,[@R89] no studies in this review discussed these factors. Furthermore, no studies evaluated group-based interventions, although the involvement of peers or family members in physiotherapeutic interventions can enhance motivation, social support and long-term participation in physical activity.[@R90] There is no doubt that the role of families is worthy of further investigation.

Outcome measures {#s4-6}
----------------

Consensus and validation of outcome measures for individuals with MJD is required, with consideration given to outcomes in terms of all the domains of the *'*Staying Strong' Framework. Reaching agreement on recommended outcome measures for people with MJD will be an important step for future clinical trials and development of clinical guidelines for management of MJD over the course of the disease. Guidelines for people with inherited ataxias have been developed,[@R91] as have guidelines for those with Friedreich's ataxia,[@R92] but the particular issues individuals and their families with MJD face require specific attention.

Limitations {#s4-7}
-----------

There were few studies that contained participants exclusively with MJD, so it is difficult to draw conclusions specifically for people with MJD. However, the findings do highlight the dearth of evidence relating to walking and moving around for individuals with MJD. While there may be interventions trialled that have had a positive impact on functional mobility, they are yet to be evaluated. Additional studies may exist that focus on domains such as having 'something important to do', 'keeping yourself happy' and 'families helping each other', but these may not have been found on initial searches if they did not include a functional mobility-related keyword. However, search strategies in this review were used to identify interventions that promoted functional mobility through staying strong both on the inside and outside.

Conclusion {#s5}
==========

This scoping review mapped studies that investigated the range of interventions to keep people with MJD walking and moving around. Findings were compared with 'what works best' according to families with MJD from the Groote Eylandt Archipelago. Interventions which aligned with their 'Staying Strong' Framework[@R18] were largely limited to staying strong on the outside (physically), with little reflection on staying strong on the inside (emotionally, mentally and spiritually). The findings of this review suggest future research is required to investigate the benefit of lifestyle activity programmes that address both physical and psychosocial well-being for families with MJD. Detailed reporting on the physical and psychosocial aspects of these interventions, and on the development and delivery of these programmes will help guide programme implementation for health service providers and clinicians working alongside families with MJD. The 'Staying Strong' Framework presented community and culturally founded needs that provided a way to identify significant gaps in the literature and highlight where those needs have not been met. Considerably more effort in culturally informed research is required.
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